Artiva Biotherapeutics In... (ARTV)
| Bid | 2.12 |
| Market Cap | 57.25M |
| Revenue (ttm) | 251K |
| Net Income (ttm) | -55.19M |
| EPS (ttm) | -5.81 |
| PE Ratio (ttm) | -0.4 |
| Forward PE | -2.13 |
| Analyst | Buy |
| Ask | 2.28 |
| Volume | 204,597 |
| Avg. Volume (20D) | 276,826 |
| Open | 2.03 |
| Previous Close | 1.96 |
| Day's Range | 1.93 - 2.35 |
| 52-Week Range | 1.78 - 17.31 |
| Beta | 5.29 |
About ARTV
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vascu...
Analyst Forecast
According to 6 analyst ratings, the average rating for ARTV stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 751.06% from the latest price.
Stock Forecasts
9 months ago · seekingalpha.com
U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO WeekA handful of IPOs priced this past week, led by three sizable names. One large issuer joined both the pipeline and the calendar - Chile-based LATAM Airlines Group. Six IPOs are scheduled to list in th...